PRX and metabolic dysfunction-associated steatohepatitis: On the other hand, as shown in Fig. 5 B, treatment with βCD-PRX significantly but partially suppressed the number of TFE3-positive macrophages in CLS, suggesting the involvement of other factors in the induction of lysosomal stress in macrophages during the development of NASH.